2024

• Färber J, Kaasch AJ, Schalk E.
  Shorter time-to-positivity and turnaround time with mycosis blood culture bottles when detecting Candida albicans.
  Infection 2024;52(2):701-703
  Imp.-Fact.:7,5
• Bechmann L, Bauer K, Zerban P, Esser T, Tersteegen A, Fuchs SA, Kaasch AJ, Wolleschak D, Schalk E, Fischer T, Mougiakakos D, Geginat G.
  Prevention of Legionella infections from toilet flushing cisterns.
  J Hosp Infect 2024;146:37-43
  Imp.-Fact.:6,9
• Zeremski V, Adolph L, Beer S, Berisha M, Jacobs B, Kahl C, Koenecke C, Kropf S, Panse J, Petersen J, Schmidt-Hieber M, Schneider J, Vucinic V, Walter J, Weigert O, Witte HM, Mougiakakos D.
  Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
  Eur J Haematol. 2024 Jan 2.Online ahead of print
  Imp.-Fact.:3,1
• Schalk, E, Pelz AF.
  Auer rods in mature granulocytes in peripheral blood.
  Int J Hematol 2024;119(2):105-106
  Imp.-Fact.:2,1

2023

• Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G.
  CD19-targeted CAR T cells in refractory antisynthetase syndrome.
  Lancet. 2023 Mar 11;401(10379):815-818.
  Imp.-Fact.:168,9
• Schett G, Mackensen A, Mougiakakos D.
  CAR T-cell therapy in autoimmune diseases.
  Lancet. 2023 Sep 22:S0140-6736(23)01126-1.
  Imp.-Fact.:168,9
• Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T.
  CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours.
  Nature. 2023 Jun;618(7967):1033-1040.
  Imp.-Fact.:64,8
• Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, Schett G, Schroers R, Gold R, Mougiakakos D.
  Anti-CD19 CAR T cells for refractory myasthenia gravis.
  Lancet Neurol. 2023 Dec;22(12):1104-1105.
  Imp.-Fact.:48
• Schalk E, Panse J.
  Which trial do we need? Scheduled central venous catheter (CVC) removal vs. routine clinical care for prevention of CVC-related bloodstream infections in patients with haematological malignancies.
  Clin Microbiol Infect 2023; 29(4):417-418
  Imp.-Fact.:13,31
• Bruch PM, Dietrich S, Finel H, Boumendil A, Greinix H, Heinicke T, Bethge W, Beelen D, Schmid C, Martin H, Castagna L, Scheid C, Schäfer-Eckart K, Bittenbring J, Finke J, Sengeloev H, Heiblig M, Cornelissen J, Chevallier P, Mohty M, Robinson S, Montoto S, Dreger P.
  Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters.
  Leukemia. 2023 Feb;37(2):465-472.
  Imp.-Fact.:12,883
• Baur R, Karl F, Böttcher-Loschinski R, Stoll A, Völkl S, Gießl A, Flamann C, Bruns H, Schlötzer-Schrehardt U, Böttcher M, Schewe DM, Fischer T, Jitschin R, Mackensen A, Mougiakakos D.
  Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy.
  J Immunother Cancer. 2023 Mar;11(3):e006362.
  Imp.-Fact.:12,485
• Pugliese GM, Venafra V, Bica V, Massacci G, Latini S, Graziosi S, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F.
  Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
  Leukemia. 2023 May;37(5):1151-1155.
  Imp.-Fact.:11,4
• Giesen N, Busch E, Schalk E, Beutel G, Rüthrich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Krüger W, Koldehoff M, Krause R, Mellinghoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermann K, Sprute R, Stemler J, Weissinger F, Wörmann B, Wolf HH, Cornely OA, Rieger CT, von Lilienfeld-Toal M.
  AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variant.
  Eur J Cancer 2023;181:102-118
  Imp.-Fact.:10
• Schubert ML, Bethge WA, Ayuk FA, von Bonin M, Vucinic V, Wagner-Drouet EM, Subklewe M, Baldus CD, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp MS, Wulf GG, Kröger N, Dreger P.
  Outcomes of axicabtagene ciloleucel in PMBCL compare favorably to DLBCL: a GLA/DRST registry study.
  Blood Adv. 2023 Aug 21:bloodadvances.2023011203, Epub ahead of print
  Imp.-Fact.:7,6
• Blumenberg V, Galina B, Baumann S, Jitschin R, Iacoboni G, Hoster E, Gallur L, Iraola-Truchuelo J, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy FJ, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M.
  Early quantification of anti-CD19 CAR T-cells by flow cytometry predicts response in R/R DLBCL.
  Blood Adv. 2023 Sep 25:bloodadvances.2023010364, Epub ahead of print
  Imp.-Fact.:7,6
• Hentrich M, Böll B, Teschner D, Panse J, Schmitt T, Naendrup JH, Schmidt-Hieber M, Neitz J, Fiegle E, Schalk E.
  Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registry.
  Infection 2023;51(4):1153-1159
  Imp.-Fact.:7,455
• Häselbarth L, Karow A, Mentz K, Böttcher M, Roche-Lancaster O, Krumbholz M, Jitschin R, Mougiakakos D, Metzler M.
  Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
  Cancer Immunol Immunother. 2023 Jan 5
  Imp.-Fact.:6,63
• Treiber H, Nilius-Eliliwi V, Seifert N, Vangala D, Wang M, Seidel S, Mika T, Marschner D, Zeremski V, Wurm-Kuczera R, Caillé L, Chapuy CI, Trümper L, Fischer T, Altenbuchinger M, Wulf GG, Illerhaus G, Dietrich S, Schroers R, Chapuy B.
  Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients.
  Hemasphere. 2023;7:e926
  Imp.-Fact.:6,6
• CAR T cells for treating autoimmune diseases.
  Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S.
  RMD Open. 2023 Nov 23;9(4):e002907.
  Imp.-Fact.:6,2
• Surov A, Meyer HJ, Hinnerichs M, Ferraro V, Zeremski V, Mougiakakos D, Saalfeld S, Wienke A, Strobel A, Wolleschak D.
  CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
  Eur Radiol. 2023 May 13.
  Imp.-Fact.:5,9
• Stemler J, Mellinghoff S, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, Hoenigl M, Krause R, Schmidt-Hieber M, Heinz W, Klein M, Koehler P, Liss B, Koldehoff M, Buhl C, Penack O, Maschmeyer G, Schalk E, Lass-Flörl C, Karthaus M, Ruhnke M, Cornely O, Teschner D.
  Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
  J Antimicrob Chemother 2023;78(8):1813-1826
  Imp.-Fact.:5,76
• Jantz-Naeem N, Böttcher-Loschinski R, Borucki K, Mitchell-Flack M, Böttcher M, Schraven B, Mougiakakos D, Kahlfuss S.
  TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment.
  Front Oncol. 2023 Feb 17;13:1060112.
  Imp.-Fact.:5,738
• Haage TR, Schraven B, Mougiakakos D, Fischer T.
  How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
  Cancers (Basel). 2023 May 30;15(11):2991.
  Imp.-Fact.:5,2
• Zeremski V, Kropf S, Koehler M, Gebauer N, McPhail ED, Habermann T, Schieppati F, Mougiakakos D.
  Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis.
  Front Oncol. 2023 Jul 20;13:1188478
  Imp.-Fact.:4,7
• Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, Neurath MF, Mougiakakos D.
  Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma.
  Front Oncol. 2023 May 22;13:1149450.
  Imp.-Fact.:4,7
• Geßner D, Berisha M, Esser T, Schalk E.
  Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies – a retrospective single-centre analysis of 200 cases.
  Ann Hematol 2023;102(9):2607-2616
  Imp.-Fact.:4,03
• Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN).
  Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
  Ann Hematol. 2023 Feb;102(2):349-358.
  Imp.-Fact.:4,03
• Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS.
  Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
  Ann Hematol. 2023 Mar;102(3):547-561.Epub 2023 Jan 25.
  Imp.-Fact.:4,03
• Schalk E, Jentsch-Ullrich K.
  Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
  Ann Hematol 2023;102(6):1617-1620
  Imp.-Fact.:4,03
• Häselbarth L, Gamali S, Saul D, Krumbholz M, Böttcher-Loschinski R, Böttcher M, Zou D, Metzler M, Karow A, Mougiakakos D.
  Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
  BMC Cancer. 2023 Nov 27;23(1):1153.
  Imp.-Fact.:3,8
• Reimann AM, Schalk E, Jost F, Mougiakakos D, Weber D, Döhner H, Récher C, Dumas PY, Ditzhaus M, Fischer T, Sager S.
  AML consolidation therapy: timing matters.
  J Cancer Res Clin Oncol 2023;149(15):13811-13821
  Imp.-Fact.:3,6
• Zeremski V, McPhail ED, Habermann TM, Schieppati F, Gebauer N, Vassilakopoulos TP, Mougiakakos D.
  Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled analysis.
  Hematol Oncol. 2023 Mar 21.
  Imp.-Fact.:3,3
• Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P.
  Long-Term Survivors After Failure of CAR-T Cell Therapy for Large B-Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A GLA/DRST Analysis.
  Transplant Cell Ther. 2023 Sep 12:S2666-6367(23)01547-6.
  Imp.-Fact.:3,2
• Teschner D, Berisha M, Panse P, Schmitt T, Fiegle E, Naendrup JH, Neitz J, Schmidt-Hieber M, Hentrich M, Böll B, Schalk E.
  Chlorhexidine gluconate-coated gel pad dressings for prevention of central venous catheter-related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry-based matched-pair analysis.
  Eur J Haematol 2023; im Druck
  Imp.-Fact.:3,1

2022

• Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G.
  Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
  Nat Med. 2022 Oct;28(10):2124-2132, Epub 2022 Sep 15.
  Imp.-Fact.:87,241
• Karl F, Liang C, Boettcher-Loschinski R, Stoll A, Flamann CS, Richter S, Lischer C, Völkl S, Jacobs B, Böttcher M, Jitschin R, Bruns H, Fischer T, Holler E, Roesler W, Dandekar T, Mackensen A, Mougiakakos D.
  Oxidative DNA Damage in Reconstituting T-cells is Associated with Relapse and Inferior Survival Following Allo-SCT.
  Blood. 2022 Dec 23:blood.2022017267.
  Imp.-Fact.:25,476
• Bogeska, Ruzhica; Mikecin, Ana-Matea; Kaschutnig, Paul Emanuel; Fawaz, Malak; Büchler-Schäff, Marleen; Le, Duy; Ganuza, Miguel; Vollmer, Angelika; Paffenholz, Stella V.; Asada, Noboru; Rodriguez-Correa, Esther; Frauhammer, Felix; Buettner, Florian; Ball, Melanie; Knoch, Julia; Stäble, Sina; Walter, Dagmar; Petri, Amelie; Carreño-Gonzalez, Martha J.; Wagner, Vinona; Brors, Benedikt; Haas, Simon; Lipka, Daniel; Essers, Marieke; Weru, Vivienn; Holland-Letz, Tim; Mallm, Jan-Philipp; Rippe, Karsten; Krämer, Stephan; Schlesner, Matthias; McKinney Freeman, Shannon; Florian, Maria Carolina; King, Katherine Y.; Frenette, Paul S.; Rieger, Michael A.; Milsom, Michael
  Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging
  Cell stem cell - Amsterdam [u.a.]: Elsevier, Bd. 29 (2022), 8, S. 1273-1284.e8, insges. 12 S.
  Imp.-Fact.:25,269
• Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp MS, Fante MA, Schroers R, Bayir LM, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P.
  GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
  Blood. 2022 Mar 22:blood.2021015209.
  Imp.-Fact.:23,629
• Weichenhan, Dieter; Lipka, Daniel; Lutsik, Pavlo; Goyal, Ashish; Plass, Christoph.
  Epigenomic technologies for precision oncology.
  Seminars in cancer biology - London: Academic Press, 1995, Bd. 84 (2022), S. 60-68, insges. 9 S.
  Imp.-Fact.:17,012
• Frišcic J, Reinwald C, Böttcher M, Houtman M, Euler M, Chen X, Walker KI, Kirchner P, Zhu H, Wirth B, Weidner D, Krüger R, Trajkovic V, Ekici AB, Klein K, Mougiakakos D, Ospelt C, Schett G, Hoffmann MH
  Reset of inflammatory priming of joint tissue and reduction of the severity of arthritis flares by bromodomain inhibition.
  Arthritis Rheumatol. 2022 Oct 17, Online ahead of print.
  Imp.-Fact.:15,48
• Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M.
  The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
  J Immunother Cancer. 2022 May;10(5):e004475.
  Imp.-Fact.:13,751
• Massacci G, Venafra V, Latini S, Bica V, Pugliese GM, Graziosi S, Klingelhuber F, Krahmer N, Fischer T, Mougiakakos D, Boettcher M, Perfetto L, Sacco F.
  A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
  Leukemia. 2022 Dec 12.
  Imp.-Fact.:12,255
• Koehler M, Hoppe S, Kropf S, Lux A, Bartsch R, Holzner B, Krauter J, Florschütz A, Jentsch-Ullrich K, Frommer J, Flechtner HH, Fischer T.
  Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies.
  J Natl Compr Canc Netw. 2022 Apr 11:1-15.
  Imp.-Fact.:11,908
• Perner, Florian; Schnöder, Tina; Xiong, Yijun; Jayavelu, Ashok Kumar; Mashamba, Nomusa; Santamaria, Nuria Tubio; Huber, Nicolas; Todorova, Kristina; Hatton, Charles; Perner, Birgit; Eifert, Theresa; Murphy, Ciara; Hartmann, Maximilian; Höll, Jessica; Schröder, Nicolas Wolfgang Jörg; Brandt, Sabine; Hochhaus, Andreas; Mertens, Peter Rene; Mann, Matthias; Armstrong, Scott A.; Mandinova, Anna; Heidel, Florian.
  YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.
  Leukemia - London: Springer Nature, 1997, Bd. 36 (2022), 2, S. 426-437.
  Imp.-Fact.:11,582
• Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K.
  Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
  K.Leukemia. 2022 Jan;36(1):90-99.
  Imp.-Fact.:11,529
• Schalk E, Biehl LM, Böll B.
  Jugular vein inserted central venous catheters (CVC) and the risk of CVC-related bloodstream infections in patients with hematological malignancies.
  Am J Hematol 2022;97(9):E336-E340
  Imp.-Fact.:10
• Urbanczyk S, Baris OR, Hofmann J, Taudte RV, Guegen N, Golombek F, Castiglione K, Meng X, Bozec A, Thomas J, Weckwerth L, Mougiakakos D, Schulz SR, Schuh W, Schlötzer-Schrehardt U, Steinmetz TD, Brodesser S, Wiesner RJ, Mielenz D.
  Mitochondrial respiration in B lymphocytes is essential for humoral immunity by controlling the flux of the TCA cycle.
  Cell Rep. 2022 Jun 7;39(10):110912.
  Imp.-Fact.:9,995
• Meier, Ruth; Greve, Gabriele; Zimmer, Dennis; Bresser, Helena; Berberich, Bettina; Langova, Ralitsa; Stomper, Julia; Rubarth, Anne; Feuerbach, Lars; Lipka, Daniel; Hey, Joschka; Grüning, Björn; Brors, Benedikt; Duyster, Justus; Plass, Christoph; Becker, Heiko; Lübbert, Michael
  The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid - in vitro and in vivo evidence for cooperation
  Blood cancer journal - London [u.a.]: Nature Publishing Group, 2011, Bd. 12 (2022), 8, S. 1-13, insges. 13 S.
  Imp.-Fact.:9,812
• Momotow J, Bühnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, Heinrich B, Gaska T, Forstbauer H, Schmidt B, Boger R, Hüttmann A, Heil G, Kraemer DM, Krüger W, Zeremski V, Grobe N, Jentsch-Ullrich K, Griesinger F, Fuchs M, von Tresckow B, Borchmann P, Engert A, Bröckelmann PJ
  Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
  Br J Haematol. 2022 Jul;198(2):401-404. 10.1111/bjh.18231. Epub 2022 May 11.
  Imp.-Fact.:8,615
• Schalk E, Schmitt T, Panse P, Fiegle E, Naendrup JH, Schmidt-Hieber M, Böll B, Hentrich M, Teschner D, Mougiakakos D.
  Central venous catheter-related bloodstream infections in patients with haematological malignancies during SARS-CoV-2 pandemic.
  Br J Haematol 2022; im Druck
  Imp.-Fact.:8,6
• Haage T, Surov A, Mougiakakos D, Berisha, M.
  Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia.
  HemaSphere: August 2022 - Volume 6 - Issue 8 - p e751
  Imp.-Fact.:8,3
• Böttcher M, Böttcher-Loschinski R, Kahlfuss S, Aigner M, Gießl A, Mackensen A, Schlötzer-Schrehardt U, Tüting T, Bruns H, Mougiakakos D.
  CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints.
  Cells. 2022 Jul 12;11(14):2176.
  Imp.-Fact.:7,66
• Reimann H, Kremer AN, Blumenberg V, Schmidt KG, Aigner M, Jacobs B, Eisenhauer N, Kämpf A, Roesler W, Kharboutli S, Mougiakakos D, Lang V, Lischer C, Irrgang P, Leppkes M, Gonzalez JV, Krönke G, Kremer AE, Tenbusch M, Bruns H, Harrer T, Müller F, Schett G, Mackensen A, Subklewe M,Völkl S.
  Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR-T cell therapy.
  Blood Adv. 2022 Oct 7:bloodadvances.2022007806, Online ahead of print.
  Imp.-Fact.:6,779
• Böttcher M, Panagiotidis K, Bruns H, Stumpf M, Völkl S, Geyh S, Dietel B, Schroeder T, Mackensen A, Mougiakakos D.
  Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset.
  Blood Adv. 2022 Apr 7:bloodadvances.2021005938.
  Imp.-Fact.:6,779
• Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T.
  Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.
  Blood Adv. 2022 Jan 25;6(2):399-404.
  Imp.-Fact.:6,779
• Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D.
  Role of CAR T Cell Metabolism for Therapeutic Efficacy.
  Cancers (Basel). 2022 Nov 4;14(21):5442.
  Imp.-Fact.:6,639
• Grünwald V, Pink D, Egerer G, Schalk E, Augustin M, Deinzer CKW, Kob V, Reichert D, Kebenko M, Brandl S, Hahn D, Lindner LH, Hoiczyk M, Ringsdorf U, Hanker LC, Hempel D, De Rivas B, Wismann T, Ivanyi P.
  Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, prospective, multicenter, phase IV trial.
  Cancers (Basel) 2022;14(21):5234
  Imp.-Fact.:6,58
• Reljic D, Herrmann HJ, Jakobs B, Dieterich W, Mougiakakos D, Neurath MF, Zopf Y.
  Feasibility, Safety, and Preliminary Efficacy of Very Low-volume Interval Training in Advanced Cancer Patients.
  Med Sci Sports Exerc. 2022 Jul 7. Online ahead of print.
  Imp.-Fact.:6,289
• Bhuria V, Baldauf CK, Schraven B, Fischer T.
  Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
  Int J Mol Sci. 2022 Mar 16;23(6):3206.
  Imp.-Fact.:5,924
• Böttcher-Loschinski R, Rial Saborido J, Böttcher M, Kahlfuss S, Mougiakakos D.
  Lipotoxicity as a Barrier for T Cell-Based Therapies.
  Biomolecules. 2022 Aug 25;12(9):1182.
  Imp.-Fact.:5,88
• Tettero, Jesse M.; Al-Badri, Waleed K. W.; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A.; Elssen, Catharina H. M. J.; Fischer, Thomas; Gjertsen, Bjorn T.; Gorkom, Gwendolyn; Gradowska, Patrycja; Greuter, Marjolein J. E.; Griskevicius, Laimonas; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G.; Pabst, Thomas; Passweg, Jakob R.; Porkka, Kimmo; Löwenberg, Bob; Ossenkoppele, Gert J.; Janssen, Jeroen J. W. M.; Cloos, Jacqueline.
  Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia - an outcome- and cost-analysis
  Frontiers in oncology - Lausanne: Frontiers Media, 2011, Bd. 12 (2022), insges. 11 S.
  Imp.-Fact.:5,738
• Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S, Lutzny-Geier G, Müller F, Mougiakakos D, Dingfelder J, Flamann C, Hanssens L, Gary R, Mackensen A, Aigner M.
  Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
  Transplant Cell Ther. 2022 Oct 12:S2666-6367(22)01699-2, Online ahead of print.
  Imp.-Fact.:5,609
• Schalk E, Hentrich M
  Real-World-Daten.
  Dtsch Arztebl Int 2022;119(8):134
  Imp.-Fact.:5,59
• Franz T, Negele J, Bruno P, Böttcher M, Mitchell-Flack M, Reemts L, Krone A, Mougiakakos D, Müller AJ, Zautner AE, Kahlfuss S
  Pleiotropic effects of antibiotics on T cell metabolism and T cell-mediated immunity.
  Front Microbiol. 2022 Oct 18;13:975436.
  Imp.-Fact.:5,59
• Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, Bethge WA; German Lymphoma Alliance (GLA); German Stem Cell Transplantation Registry (DRST).
  Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
  Bone Marrow Transplant. 2022 Nov 22.
  Imp.-Fact.:5,432
• Gizem Özkan H, Thakor V, Xu HG, Bila G, Bilyy R, Bida D, Böttcher M, Mougiakakos D, Tietze R, Mokhir A.
  Anticancer Aminoferrocene Derivatives Inducing Production of Mitochondrial Reactive Oxygen Species.
  Chemistry. 2022 Apr 13:e202104420.
  Imp.-Fact.:5,236
• Richter S, Böttcher M, Völkl S, Mackensen A, Ullrich E, Jacobs B, Mougiakakos D.
  The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome.
  Sci Rep. 2022 Jul 6;12(1):11406.
  Imp.-Fact.:4,996
• Panse J, Tölle D, Fiegle E, Naendrup JH, Schmidt-Hieber M, Böll B, Hentrich M, Teschner D, Schalk E
  Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: A registry-based randomized simulation-study.
  Ann Hematol 2022;101(10):2317-2324
  Imp.-Fact.:4
• Schalk E, Hentrich M.
  Overweight or obesity are not risk factors for central venous catheter related bloodstream infections in patients with hematological malignancies.
  Infect Control Hosp Epidemiol 2022;43(12):1953-1955
  Imp.-Fact.:3,3
• Ferraro V, Thormann M, Hinnerichs M, Pech M, Wolleschak D, Mougiakakos D, Wienke A, Strobel A, Zeremski V, Surov A, Omari J.
  Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy.
  Oncol Lett. 2022 Aug 22;24(4):355.
  Imp.-Fact.:3,111
• Hinnerichs M, Ferraro V, Zeremski V, Mougiakakos D, Omari J, Pech M, Bär C, Wienke A, Saalfeld S, Strobel A, Surov A, Meyer HJ, Wolleschak D.
  Prognostic Impact of Quality and Distribution of Adipose Tissue in Patients With Primary Central Nervous System Lymphoma.
  In Vivo. 2022 Nov-Dec;36(6):2828-2834.
  Imp.-Fact.:2,46
• Müller P, Baldauf CK, Haage TR, Charakopoulos E, Böttcher M, Bhuria V, Mougiakakos D, Schraven B, Fischer T.
  Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model.
  Hemasphere. 2022 Apr 15;6(5):e717.
• Katsounas A, Schalk E.
  Infektionszahlen um ein Vielfaches höher.
  Dtsch Arztebl Int 2022;119(15):278

2021

• Dudeck J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI , Morton L, Jahn SR, Katsoulis-Dimitriou K, Winzer S, Kollias Georg, Fischer T, Nedospasov SA, Dunay IR, Chavakis T, Müller A J, Schraven B, Sperandio M, Dudeck A.
  Directional mast cell degranulation of tumor necrosis factor intoblood vessels primes neutrophil extravasation.
  Immunity, im Druck
  Imp.-Fact.:22,553
• Osbelt L, Wende M, Almási E, Derksen E, Muthukumarasamy U, Lesker TR, Galvez EJC, Pils MC, Schalk E, Chhatwal P, Färber J, Neumann-Schaal M, Fischer T, Schlüter D, Strowig T.
  Klebsiella oxytoca causes colonization resistance against multidrug-resistant K. pneumoniae in the gut via cooperative carbohydrate competition.
  Cell Host Microbe 2021;29:1663-1679
  Imp.-Fact.:21
• Surova A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A.
  Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A Meta-Analysis.
  Clinical Nutrition, im Druck
  Imp.-Fact.:7,324
• Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M; COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
  2021 Update of the AGIHO guideline on evidence-based management of COVID-19 in cancer patients regarding diagnostics, viral shedding, vaccination and therapy.
  Eur J Cancer 2021;147:154-160
  Imp.-Fact.:7,3
• Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D.
  Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
  Ann. Hematol. 2021 Sep; 100(9):2387-2398.
  Imp.-Fact.:4,03
• Christian Straka, Hans Salwender, Stefan Knop, Martin Vogel, Jürgen Müller, Bernd Metzner, Christian Langer, Herbert Sayer, Wolfram Jung, Heinz A. Dürk, Florian Bassermann, Martin Gramatzki, Wolf Rösler, Hans-Heinrich Wolf, Wolfram Brugger, Monika Engelhardt, Thomas Fischer, Peter Liebisch, Hermann Einsele.
  Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
  Eur J Haematol. 2021, online ahead of print
  Imp.-Fact.:2,997
• Böll B, Schalk E, Buchheidt D, Hasenkamp J, Kiehl M, Kiderlen TR, Kochanek M, Koldehoff M, Kostrewa P, Claßen AY, Mellinghoff SC, Metzner B, Penack O, Ruhnke M, Vehreschild MJGT, Weissinger F, Wolf HH, Karthaus M, Hentrich M.
  Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
  Ann Hematol 2021;100(1):239-259
  Imp.-Fact.:2,9
• Schalk E, Vehreschild MJGT, Biehl LM.
  Influence of different definitions of central venous catheter-related bloodstream infections on epidemiological parameters in cancer patients.
  Infect Control Hosp Epidemiol 2021;42(4):501-503
  Imp.-Fact.:2,86
• Schmidt-Hieber M, Teschner D, Desole M, Link H, Maschmeyer G, Schalk E.
  Therapie von Infektionen bei Tumorpatienten.
  Schmoll HJ (Hrsg.), Kompendium Internistische Onkologie, 5. Auflage, Springer, 2021; im Druck

2020

• Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH, Jayavelu AK, et al.
  Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
  Nature 2020 Dec;588(7836):157-163
  Imp.-Fact.:43,07
• Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N.
  Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
  Leukemia. 2020 Nov 4.
  Imp.-Fact.:8,665
• Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA*, Köhler P*, Schalk E*, von Lilienfeld-Toal M*. (*Geteilte Letztautorenschaft)
  Evidence-based management of COVID-19 in cancer patients – Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
  Eur J Cancer 2020;140:86-104.
  Imp.-Fact.:7,3
• Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.
  Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (=60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
  Bone Marrow Transplant. 55, 729–739 (2020).
  Imp.-Fact.:5,432
• Stemler J, Bruns C, Mellinghoff SC, Alakel N, Akan H, Ananda-Rajah M, Auberger J, Bojko P, Chandrasekar PH, Chayakulkeeree M, Cozzi JA, de Kort EA, Groll AH, Heath CH, Henze L, Hernandez Jimenez M, Kanj SS, Khanna N, Koldehoff M, Lee DG, Mager A, Marchesi F, Martino-Bufarull R, Nucci M, Oksi J, Pagano L, Philips B, Prattes J, Pyrpasopoulou A, Rabitsch W, Schalk E, Schmidt-Hieber M, Sidharthan N, Soler-Palacín P, Stern A, Weinbergerová B, El Zakhem A, Cornely OA, Koehler P.
  Baseline chest computed tomography as standard of care in high-risk hematology patients.
  J Fungi (Basel) 2020;6(1):36
  Imp.-Fact.:4,62
• Jost F, Schalk E, Weber D, Doehner H, Fischer T, Sager S.
  Model-based optimal AML consolidation treatment.
  IEEE Trans Biomed Eng 2020;67(12):3296-3306
  Imp.-Fact.:4,424
• Lilienthal P, Tetschke M, Schalk E, Fischer T, Sager S.
  Optimized and personalized phlebotomy schedules for patients suffering from polycythemia vera.
  Front Physiol 2020;11:328
  Imp.-Fact.:3,2
• Zeremski V, Fischer T, Schalk E.
  Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma.
  Leuk Lymphoma. 2020 Jan;61(1):240-242
  Imp.-Fact.:3,093
• Heinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, Brecht A, Kröger N, Beelen DW, Scheid C, Bethge W, Dreger P, Bunjes D, Wagner E, Platzbecker U, Savani BN, Nagler A, Mohty M.
  Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia–a study of the Acute Leukemia Working Party of the EBMT.
  Leuk. Lymphoma (2020).
  Imp.-Fact.:2,996
• Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D,, Dirksen U,, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A.
  Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors – presentation of the CARE for CAYA-Program study protocol and associated literature review
  BMC Cancer. 2020 Jan 6;20(1)
  Imp.-Fact.:2,933
• Schalk E, Teschner D, Hentrich M, Böll B, Panse J, Schmidt-Hieber M, Vehreschild MJGT, Biehl LM.
  Central venous catheter-related bloodstream infections in patients with hematological malignancies: comparison of data from a clinical registry and a randomized controlled trial.
  Infect Control Hosp Epidemiol. 2020 Feb;41(2):254-256
  Imp.-Fact.:2,86
• Ptok H , Schalk E , Hass P , Heinze C , Brunner T , Croner RS.
  Multimodale Therapie primärer, nicht metastasierter retroperitonealer Sarkome.
  Zentralbl Chir 2020;145(5):405-416
  Imp.-Fact.:0,7
• Koehler M, Mann J, Richter D, Hilgendorf I
  Krebs bei Jugendlichen und jungen Erwachsenen. Status quo der interdisziplinären Versorgung in Deutschland
  Forum 2020 · 35:37–42

2019

• Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.
  Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results from the AML Study Group.
  Blood 134, 1608–1618 (2019).
  Imp.-Fact.:25,476
• Nimmagadda SC, Frey S, Müller P, Wolleschak D, Weinert S, Keller U, Edelmann B, Fischer T.
  SDF1a-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLC gamma 1 and RhoA.
  Haematologica. 2019 Jul;104(7):e288-e292
  Imp.-Fact.:9,09
• Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN.
  Targeting RIPK1 in AML cells carrying FLT3-ITD.
  Int J Cancer. 2019 Mar 3. [Epub ahead of print]
  Imp.-Fact.:7,36
• Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.
  Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.
  Cell Commun Signal. 2019 Jan 16;17(1):5.
  Imp.-Fact.:5,324
• Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D.
  The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma.
  Bone Marrow Transplant. 2019 Oct;54(10):1662-1667.
  Imp.-Fact.:5,174
• Salmanton-García J, Seidel D, Koehler P, Mellinghoff SC, Herbrecht R, Klimko N, Rácil Z, Falces-Romero I, Ingram P, Benítez-Peñuela MA, Rodríguez-Quintero J, Desoubeaux G, Barac A, Hoenigl M, Klyasova G, Puerta-Alcalde P, Cheng MP, Heinz WH, Iqba N, Krausen R, Ostermann H, Penack O, Schalk E, Sheppard DC, Willinger B, Wisplinghoff H, Vehreschild JJ, Cornely OA, Vehreschild MJGTZ, on behalf of The FungiScope® ECMM/ISHAM Working Group.
  Matched-paired analysis of patients treated for invasive mucormycosis - standard treatment vs. posaconazole new formulations (MoveOn).
  J Antimicrob Chemother. 2019 Nov 1;74(11):3315-3327
  Imp.-Fact.:5,113
• Schalk E, Katsounas A.
  HIV/AIDS-related refractory Kaposi sarcoma causing severe leg lymphedema.
  Open Forum Infect Dis. 2019 Sep 18;6(10):ofz407.
  Imp.-Fact.:3,371
• Schmidt-Hieber M, Teschner D, Maschmeyer G, Schalk E.
  Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.
  Expert Rev Anti-Infect Ther 2019;17(12):983-995
  Imp.-Fact.:3,141
• Probst L, Schalk E, Liebregts T, Zeremski V, Tzalavras A, von Bergwelt-Baildon M, Hesse N, Prinz J, Vehreschild JJ, Shimabukuro-Vornhagen A, Eichenauer DA, Garcia Borrega J, Kochanek M, Böll B; Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
  Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study.
  J Intensive Care 20197;7:41.
  Imp.-Fact.:3,1
• Tölle D, Hentrich M, Pelzer BW, Kremer P, Einhell S, Schulz S, Böll B, Panse J, Schmidt-Hieber M, Teschner D, Schalk E.
  Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis.
  Infect Control Hosp Epidemiol 2019;40(10):1204-1206.
  Imp.-Fact.:3,084
• Zeremski V, Jentsch-Ullrich K, Kahl C, Mohren M, Eberhardt J, Fischer T, Schalk E.
  Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B-cell lymphoma? Results from a multicenter, retrospective study.
  Ann Hematol 2019;98(12):2729-2737
  Imp.-Fact.:2,85
• Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Henze L, Hentrich M, Kiehl M, Liebregts T, von Lilienfeld-Toal M, Löhnert M, Mellinghoff S, Penack O, Piepel C, Böll B.
  Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
  Ann Hematol 2019;98(5):1051-1069
  Imp.-Fact.:2,845
• Jost F, Schalk E, Rinke K, Fischer T, Sager S.
  Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
  PLoS One 2019;14(7):e0204540.
  Imp.-Fact.:2,806
• Schalk E, Zeremski V, Fischer T.
  Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with Pseudomonas aeruginosa.
  Infection 2019;47(2):333-334
  Imp.-Fact.:2,773
• Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H.
  Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
  Eur J Haematol. 2019 Sep;103(3):255-267, Epub 2019 Jul 19.
  Imp.-Fact.:2,217
• Schalk E, Fischer T, Wolleschak D.
  Splenic cyst after abdominal trauma?
  Dtsch Arztebl Int 2019;116:362